Rare lymphoid malignancies of the breast: report of two cases illustrating potential diagnostic techniques

Orazio Schillaci¹, Laura Travascio¹, Annamaria Lacanfora¹*, Sara Ceccarelli², Giovanni Simonetti²

¹. Department of Biopathology and Diagnostic Imaging, University Tor Vergata, Rome, Italy
². Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, University Tor Vergata, Rome, Italy

* Correspondence: Annamaria Lacanfora, Department of Biopathology and Diagnostic Imaging, University Tor Vergata, Viale Oxford 81, 00173 Rome, Italy

Radiology Case. 2012 Dec; 6(12):43-50 :: DOI: 10.3941/jrcr.v6i12.1194

ABSTRACT

Two cases of lymphoid malignancy involving the breast are herein presented. Both patients were admitted with a palpable breast mass. Ultrasound demonstrated hypoechoic, ill-defined lesions of the breast in both patients; mammogram also showed spiculated breast densities. Both patients underwent core biopsy, which revealed lymphomatous cells. Total-body evaluation was also performed by computed tomography and positron emission tomography/computed tomography revealing no other fluorodeoxyglucose-avid foci in the first case and supra and subdiaphragmatic disease in the second one.

CASE REPORT

Case 1

A 77-year-old Caucasian woman without comorbidity, except diabetes type II, asthma allergy and hypertension, was admitted with a palpable lesion localized between the right breast lower quadrants. A mammogram confirmed an increased density in the lower quadrants of the right breast [Fig.1 a,b]. A diagnostic ultrasound of the right breast was then performed which revealed two ill-defined, hypoechoic, heterogeneous lesions [maximum transverse diameter (mtd) 38 mm and 20 mm] between the right lower quadrants [Fig.2 a,b], corresponding to the mass noticed at the physical exam. Computed tomography [CT] of the chest, abdomen and pelvis confirmed the right breast densities and showed no lymphadenopathy or splenomegaly. The patient subsequently underwent an ultrasound-guided right breast core biopsy for cytological evaluation [Fig.3 a,b]. Large B-cell non-Hodgkin lymphoma with high Ki-67 growth fraction, increased levels of LDH was diagnosed. Staging evaluation by PET/CT [Fig.4] revealed high-level F-18 fluorodeoxyglucose uptake (SUVmax 17.5) within the bigger nodule localized at the lower quadrants of the right breast; no other sites of FDG-avidity were identified. Ann Arbor stage was IE. The patient underwent four cycles of chemotherapy with Cyclophosphamide, Epyrubicina and Velbe [R-CHOP].

Case 2

A 69-year-old Caucasian woman with several medical comorbidities [isteroanessiectomy, urinary incontinence and bladder prolapse, hypertension and dyslipidemia] was admitted with constitutional symptoms and axillary and cervical lymph nodes enlargement. A large B-cell non-Hodgkin lymphoma was diagnosed. The patient underwent six cycles of chemotherapy with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone and Rituximab [R-CHOP]. Six months later, the patient was readmitted with a palpable lump localized between the upper quadrants of the left breast. Mammogram and ultrasound revealed one defined, hypoechoic, 17 mm heterogeneous lesion in the left upper quadrants corresponding to the mass seen on physical exam [Fig.5]. The patient subsequently underwent an ultrasound-guided left breast core biopsy, for cytological evaluation [Fig.6]. A diagnosis of recurrence of non-Hodgkin lymphoma with secondary breast lymphoma, was made. Restaging evaluation by PET/CT confirmed an FDG-avid nodule.
Rare lymphoid malignancies of the breast: report of two cases illustrating potential diagnostic techniques

DISCUSSION

No distinct mammographic or ultrasonographic features have been described in literature to differentiate breast lymphoma from breast carcinoma. Imaging characteristics on mammography or ultrasonography are also nonspecific and indistinguishable from invasive ductal or lobular carcinoma. A sarcomatous mass and fibromatoses are also in the differential and cannot be readily distinguished from lymphoma. Fat necrosis is distinguished by showing fat signal centrally within the lesion (Table 2). Definitive diagnosis is made with core biopsy allowing treatment planning. Positron emission tomography/computed tomography with F-18 flourodeoxyglucose has gained value in diagnosis and monitoring therapeutic response of many cancers, including lymphoma. Breast lymphoma (Table 1) defined as lymphoma involving the breast has been historically classified into primary breast lymphoma [PBL] and secondary breast lymphoma [SBL], including respectively 0.04% to 0.5% of malignant breast neoplasms [1]. In 1972, Wiseman and Liao [2] first proposed criteria for PBL as follows: a) adequate pathologic specimens; b) mammary tissue and lymphomatous infiltrate in close association; c) no prior diagnosis of an extramammary lymphoma and d) no evidence of concurrent widespread disease except ipsilateral axillary lymph nodes. All those patients not meeting these four criteria are considered to have SBL. And, according to these criteria, all patients with PBL have localized disease with or without regional lymph node involvement [2]. PBL represents 1% of all non-Hodgkin's lymphomas NHL [3], that is known to include a broad variety of histologic types. The majority are B-cell lymphomas, and the most common type is diffuse large B-cell lymphoma, 40% to 70%; T-cell neoplasms are rare [4]. MALT-type lymphoma (extranodal marginal zone lymphoma of Mucosa-Associated Lymphoid Tissue) is a distinct subgroup of primary lymphoma of the breast with a reported incidence between 0% and 44% according to the series reported, and is characterized by indolent behaviour and good prognosis [4,5]. Burkitt's lymphoma, peripheral T-cell lymphoma, classical Hodgkin's lymphoma, and follicular lymphoma are less commonly noticed [4-6]. Burkitt's or Burkitt-like lymphoma, that involves the breast of a young pregnant or lactating woman, typically behaves aggressively. SBL may display a similar histologic behavior with an increased frequency of follicular subtype lymphoma, though prognosis is still influenced by the primary lymphoma stage [7-11]. Prognosis of patients with breast lymphoma can range from 26 to 66% 5-years survival rates [12], with diffuse large B-cell type breast lymphoma displaying the worst prognosis. Also, the latter has a significant risk of contralateral breast involvement (5%) [13]. The Extra Nodal Lymphoma Study Group, ENLSG, also noted that young age and stage IIE disease are associated with poorer prognoses. Herein we report 2 cases of patients with palpable breast lesions, confirmed by mammography (Mx), ultrasonography (US) and CT, and then staged with F-18 FDG PET/CT. Mammary lumps, at first presentation, show (Table 2) as a stellate nodule or with typical BIIRADS (Breast Imaging Reporting and Data System) calcification pattern on Mx [14], usually corresponding to a heterogeneous hypoechoic lesion on the US. Cytological sample is mandatory in nodules with those imaging features [14] to correctly plan a diagnostic and therapeutic approach. Patients herein presented were staged by means of F18 FDG PET/CT only, while patients with breast cancer also undergo bone scan.

The patients underwent four cycles of chemotherapy and were followed by PET/CT to evaluate response to treatment. Breast lymphoma treatment includes systemic chemotherapy (in most cases R-CHOP) [12-15], and local radiation therapy, because of their high chemoresistance [16-18]. Kim et al. [18] reported that a short course of chemotherapy followed by local radiation therapy was a safe approach for stage IAE disease. On the other hand, a combination of full-course chemotherapy and local radiation therapy, or even bone marrow transplant, [16-18] has to be considered for stage IIAE disease and recurrent disease, respectively.

TEACHING POINT

Correct histologic characterisation of a suspect breast lesion is important, as diagnostic and therapeutic approach may change significantly. Lymphoma of the breast is rare, but has to be considered in the differential diagnosis when a breast mass is seen. The presented case highlights how PET-CT correctly staged and restaged an oncologic disease, influencing the therapeutic scheme.

REFERENCES


Radiology Case. 2012 Dec; 6(12):43-50
Nuclear Medicine / Molecular Imaging: Rare lymphoid malignancies of the breast: report of two cases illustrating potential diagnostic techniques

Schillaci et al.


17. Brogi E, Harris NL. Lymphomas of the breast: Pathology and clinical behavior. Semin Oncol. 1999; 26:357-64. PMID: 10375092


FIGURES

Figure 1: 77-year-old Caucasian woman with Large B-cell non-Hodgkin lymphoma of the right breast. Mammography of patient n 1. 1a: Right breast CC projection digital mammogram (Hologic Selenia Digital Mammography Unit). 1b: Right breast MLO projection digital mammogram. Images showing an ill-defined density in the retroareolar [1a] lower quadrants [1b] (arrows).
Figure 2: 77-year-old Caucasian woman with Large B-cell non-Hodgkin lymphoma of the right breast (a,b). US of the right breast, which reveals two intraparenchymal ill-defined hypoechoic heterogenous lesions (arrows) corresponding to a palpable mass on physical exam in the lower quadrants (respectively 19.5 and 45 mm).
PROTOCOL: iU22 with a probe center frequency of 9-12 MHz (Philips).

Figure 3: 77-year-old Caucasian woman with Large B-cell non-Hodgkin lymphoma of the right breast. The lymphoma contained medium to large monoclonal B cells positive for CD45, CD19, CD20, CD10, BCL-2, BCL-6 kappa+/lambda-. The lymphomatous lesions were all negative for CD5, CD10, and CD23. a). Lymphoid pattern of the lesion found in the right breast. b). Large B cell Lymphoma well defined on higher magnification x40.
Figure 4: 77-year-old Caucasian woman with Large B-cell non-Hodgkin lymphoma of the right breast. In (a), the maximum intensity projection [MIP] of patient no. 1, which shows a single FDG-avid focus of activity (black arrow), corresponding to (b) a 27x15 mm mammary nodule (SUVmax 17.5) in the right inner lower quadrant with high FDG uptake (c) in the axial CT and fused PET/CT images (white arrows). PROTOCOL: PET/CT system Discovery ST16, (GE Medical Systems, TN, USA) was used. A low dose CT scan was acquired for attenuation correction of PET images [80 mAs, 140 kVp, field of view (FOV) about 420-500mm, CT slice thickness 3.75]. After nonenhanced CT, total-body PET examination in the caudocranial direction, from upper thighs to vertex, was performed (two bed positions, 4 min per bed). Images were reconstructed using a standard iterative algorithm [ordered subsets expectation maximisation (OSEM)] after 25-30 min of acquisition. Contrast-enhanced CT scan [120-140 kVp, automatic milliamperage (limit 330-350mA), thickness 3.750 mm (reconstructed at 1.25 mm), acquisition mode 27.50/1.375:1, gantry rotation time 0.6 s, large FOV, matrix 512×512] was carried out with i.v. administration of nonionic iodinated contrast material (100-120 ml, 370 mgI/ml, at 2-2.5 ml/s), obtaining two successive stacks of scans. The first comprised the upper abdomen with a 30-s delay from the injection onset; the second extended from the neck to the pelvis with a 60-s delay.

Figure 5 (left): A 69-year-old Caucasian woman with non-Hodgkin lymphoma of the left breast. US which reveals an intraparenchymal ill-defined hypoechoic heterogenous lesion (arrow) corresponding to a palpable mass on physical exam in the upper left quadrants (17 mm).
PROTOCOL: iU22 with a probe center frequency of 9-12 MHz (Philips).
Figure 6: A 69-year-old Caucasian woman with non-Hodgkin lymphoma of the left breast. The lesion was a non-Hodgkin, grade II, germinal-center lymphoma of Bcell origin and exhibited a nodular pattern (> 75%) (a). More specifically, the nodules were formed by cells with morphology of centroblasts and centrocytes; the number of centroblasts did not exceed 15 per optical field (×40). The stroma exhibited hyalinization where the malignant lymphoid tissue was present. The malignant lymphoid cells were occasionally present within the fatty breast tissue, and a few entrapped mammary ducts were recognized within the sclerotic stroma. Immunohistochemically, the lymphoid cells were positive for CD20, bcl-2 (b) and CD10, whereas some CD10-positive cells were present outside the nodules. There was indication of kappa chain clonality. The Ki-67 proliferation marker was positive in 10% of cells.

Figure 7: A 69-year-old Caucasian woman with non-Hodgkin lymphoma of the left breast. In (a) MIP of patient. no.2, showing pathologic FDG-uptake (SUVmax 22) in the 13x18 mm mammary nodule (black arrow) localized at the upper outer quadrant of the left breast. Other areas of pathologic FDG uptake were noticed in a paracaval node and in several multiple mesenteric nodes, better seen respectively in the axial CT and PET/CT fuse images (b-c) (white arrows). PROTOCOL: The PET/CT system Discovery ST16, (GE Medical Systems, TN, USA) was used. A low dose CT scan was acquired for attenuation correction of PET images [80 mAs, 140 kVp, field of view (FOV) about 420-500mm, CT slice thickness 3.75]. After nonenhanced CT, total-body PET examination in the caudocranial direction, from upper thighs to vertex, was performed (two bed positions, 4 min per bed). Images were reconstructed using a standard iterative algorithm [ordered subsets expectation maximisation (OSEM)] after 25-30 min of acquisition. Contrast-enhanced CT scan [120-140 kVp, automatic milliamperage (limit 330-350mA), thickness 3.750 mm (reconstructed at 1.25 mm), acquisition mode 27.50/1.375:1, gantry rotation time 0.6 s, large FOV, matrix 512×512] was carried out with i.v. administration of nonionic iodinated contrast material (100-120 ml, 370 mgI/ml, at 2-2.5 ml/s).
Rare lymphoid malignancies of the breast: report of two cases illustrating potential diagnostic techniques

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Lymphocytic infiltrate within the breast epithelium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>0.04% to 0.5% of malignant breast neoplasms</td>
</tr>
<tr>
<td>Gender ratio</td>
<td>Affects females</td>
</tr>
<tr>
<td>Age predilection</td>
<td>Mean age 37, range 13-80 years</td>
</tr>
<tr>
<td>Risk factors</td>
<td>• Exogenous hormone treatments</td>
</tr>
<tr>
<td></td>
<td>• Immunodeficiencies, autoimmune diseases</td>
</tr>
<tr>
<td></td>
<td>• Infectious agents, chemical and physical</td>
</tr>
<tr>
<td>Treatment</td>
<td>• Surgery</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy</td>
</tr>
<tr>
<td></td>
<td>• Local radiation therapy</td>
</tr>
<tr>
<td></td>
<td>• Bone marrow transplant</td>
</tr>
<tr>
<td>Prognosis</td>
<td>• Range from 26 to 66% 5-years survival rates</td>
</tr>
<tr>
<td></td>
<td>• Response to medical treatment variable</td>
</tr>
<tr>
<td></td>
<td>• Spontaneous regression rare</td>
</tr>
<tr>
<td></td>
<td>• Possible relapse either local, in PBL, or distant, in SBL</td>
</tr>
<tr>
<td>Imaging findings</td>
<td>Mammmogram: ill-defined density</td>
</tr>
<tr>
<td></td>
<td>Ultrasound: ill-defined hypoechoic heterogeneous lesions</td>
</tr>
<tr>
<td></td>
<td>PET/CT: Typically high FDG avidity</td>
</tr>
</tbody>
</table>

**Table 1:** Summary table for breast lymphoma.

<table>
<thead>
<tr>
<th>Breast fibromatosis</th>
<th>Invasive ductal carcinoma</th>
<th>Fat necrosis</th>
<th>Breast lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mammography</strong></td>
<td>Irregular dense mass with spiculated margins</td>
<td>Irregular spiculated margins</td>
<td>Lucent center, peripheral rim of calcification</td>
</tr>
<tr>
<td><strong>Ultrasound</strong></td>
<td>Hypoechoic, irregular shape, spiculated margins</td>
<td>Irregular hypoechoic shadowing mass</td>
<td>Acute phase: echogenic structure Subacute phase: ill-defined complex cyst Late phase: calcified echogenic walls</td>
</tr>
<tr>
<td><strong>PET/CT</strong></td>
<td>Low or no FDG avidity</td>
<td>Typically high FDG avidity</td>
<td>Typically high FDG avidity</td>
</tr>
</tbody>
</table>

**Table 2:** Differential table for breast tumors (not all-embracing).
ABBREVIATIONS

BIRADS: Breast Imaging Reporting and Data System
CT: Computed Tomography
ENLSG: Extra nodal lymphoma Study Group
F-18: Fluorine-18
FDG: Fludeoxyglucose
IGEV gemcitabine,vinorelbine, ifosfamide and prednisone
MALT: mucosa-associated lymphoid tissue
MIP: Maximum Intensity Projection
Mtd: Maximum transverse diameter
Mx: Mammography
NHL: non-Hodgkin's lymphomas
PBL: Primary breast lymphoma
PET: Positron Emission Tomography
R-CHOP: Rituximab- Cyclophosphamide-
Hydroxydaunorubicin- Oncovin- Prednisone
SBL: Secondary breast lymphoma
SUV: Standard Uptake Value
SUVmax: Maximum Standard Uptake Value
US: Ultrasound

KEYWORDS

Breast; lymphoma; primary breast lymphoma; secondary breast lymphoma

ACKNOWLEDGEMENTS

This work was supported by grant from "Università di Roma Tor Vergata", Italy.

Online access

This publication is online available at:

Peer discussion

Discuss this manuscript in our protected discussion forum at:
www.radiolopolis.com/forums/JRCR

Interactivity

This publication is available as an interactive article with scroll, window/level, magnify and more features.
Available online at www.RadiologyCases.com

Published by EduRad

www.EduRad.org